GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » PB Ratio

AbCellera Biologics (AbCellera Biologics) PB Ratio : 0.97 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-29), AbCellera Biologics's share price is $3.84. AbCellera Biologics's Book Value per Share for the quarter that ended in Dec. 2023 was $3.96. Hence, AbCellera Biologics's PB Ratio of today is 0.97.

Good Sign:

AbCellera Biologics Inc stock PB Ratio (=0.95) is close to 5-year low of 0.95

The historical rank and industry rank for AbCellera Biologics's PB Ratio or its related term are showing as below:

ABCL' s PB Ratio Range Over the Past 10 Years
Min: 0.95   Med: 2.39   Max: 175.3
Current: 0.97

During the past 6 years, AbCellera Biologics's highest PB Ratio was 175.30. The lowest was 0.95. And the median was 2.39.

ABCL's PB Ratio is ranked better than
80.99% of 1310 companies
in the Biotechnology industry
Industry Median: 2.375 vs ABCL: 0.97

During the past 12 months, AbCellera Biologics's average Book Value Per Share Growth Rate was -7.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 8.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 265.10% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of AbCellera Biologics was 631.10% per year. The lowest was 8.70% per year. And the median was 497.20% per year.

Back to Basics: PB Ratio


AbCellera Biologics PB Ratio Historical Data

The historical data trend for AbCellera Biologics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics PB Ratio Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 13.06 3.95 2.36 1.44

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 1.80 1.55 1.13 1.44

Competitive Comparison of AbCellera Biologics's PB Ratio

For the Biotechnology subindustry, AbCellera Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's PB Ratio distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's PB Ratio falls into.



AbCellera Biologics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

AbCellera Biologics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=3.84/3.962
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


AbCellera Biologics  (NAS:ABCL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


AbCellera Biologics PB Ratio Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (AbCellera Biologics) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Executives
John S. Montalbano director C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault director, officer: Chief Operating Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd. 10 percent owner 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth officer: Chief Financial Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer director, 10 percent owner PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer officer: Chief Technology Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G. director, 10 percent owner, officer: Chief Executive Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart officer: Chief Legal Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel director 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p. 10 percent owner 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301